Form 4: Turnstone Biologics Director Gupta Acquires Stock Options

Director Rishi Gupta of Turnstone Biologics Corp. acquired stock options for 12,770 shares at an exercise price of $2.69 on June 3, 2024.

Summary

• Rishi Gupta, a director of Turnstone Biologics Corp., filed a Form 4 indicating a change in beneficial ownership.
• On June 3, 2024, Gupta acquired stock options for 12,770 shares of common stock at an exercise price of $2.69 per share.
• The options vest on the earlier of June 3, 2025, or the date of the next annual meeting of stockholders, contingent upon continuous service.
• Gupta is obligated to transfer any securities or economic benefits from these options to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which will then provide them to OrbiMed Private Investments VI, LP.
• Following the transaction, Gupta directly owns 12,770 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which is neither overwhelmingly positive nor negative.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Risks

• The obligation to transfer securities or economic benefits to OrbiMed entities might limit Gupta's direct financial gain from the options.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance beyond the vesting schedule of the options.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. This filing indicates a change in the beneficial ownership of a director at Turnstone Biologics, which is common in publicly traded companies.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors and executives in the biotechnology industry.
• The vesting schedule and exercise price are typical for such grants, aligning the director's interests with those of the shareholders.
• Companies like Amgen, Gilead Sciences, and Biogen also use stock options as part of their compensation packages.

Related Party Transactions

• The Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefits thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI, LP.

Stakeholder Impact

• The stock option grant could potentially align the director's interests with those of the shareholders, encouraging actions that increase shareholder value.

Key Dates

Keywords

Form 4, beneficial ownership, stock options, Turnstone Biologics, TSBX, Rishi Gupta, OrbiMed